OPTINOSE INC. - COMMO

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights

12 Nov 2024 07:00:12 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

05 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Optinose Appoints Terry Kohler as Chief Financial Officer

07 Oct 2024 16:59:53 By Nasdaq GlobeNewswire

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

05 Sep 2024 09:00:50 By Nasdaq GlobeNewswire

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

26 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

08 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Second Quarter 2024 Financial Results

02 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Expanded Access to XHANCE with Addition to National Commercial Formularies

27 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

17 May 2024 12:00:00 By Nasdaq GlobeNewswire

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for First Quarter 2024 Financial Results

10 May 2024 14:57:13 By Nasdaq GlobeNewswire

Optinose Announces $55 Million Registered Direct Offering

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Optinose to Present at the Needham Virtual Healthcare Conference

04 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

15 Mar 2024 15:34:50 By Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

07 Mar 2024 07:00:43 By Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

29 Feb 2024 16:40:00 By Nasdaq GlobeNewswire

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

18 Jan 2024 12:00:00 By Nasdaq GlobeNewswire

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

06 Dec 2023 07:00:00 By Nasdaq GlobeNewswire